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Summary
Nearly half a century has passed since the first pub-
lished description of interferons (IFNs). This commen-
tary introduces the four accompanying review articles
on type I IFN research and attempts to relate how the
field of IFN research has been changing during its
history.
Interferon (IFN) was first described as a product of influ-
enza virus-infected chick embryo cells, capable of in-
ducing resistance to infection with homologous or het-
erologous viruses (Isaacs and Lindenmann, 1957).
Some years later, a functionally related protein (now
called IFN-g or type II IFN) was described as an IFN-
like virus-inhibitory protein produced by mitogen-acti-
vated human T lymphocytes (Wheelock, 1965). Type I
IFNs include numerous subtypes, of which IFN-a and
IFN-b are the predominant forms (see review by van
Boxel-Dezaire et al., 2006 in this issue of Immunity).
Twelve separate functional IFN-a genes and proteins
and a single IFN-b gene exist in humans.
Touted as a potentially useful antiviral drug, the study
of IFN from the very beginning attracted wide attention.
In the 1960s, Flash Gordon magazine featured a comic
strip in which doctors in a space ship used IFN to cure
a patient afflicted with a mysterious virus infection. Nev-
ertheless, because efforts to purify and molecularly de-
fine IFN proteins remained fruitless for about 20 years,
many scientists had been openly skeptical about prop-
erties ascribed to IFN, including its very existence. It
was only after the successful cloning of IFN cDNAs
and identification of IFN genes that IFN research joined
the mainstream of the scientific enterprise (Gray and
Goeddel, 1982; Nagata et al., 1980; Taniguchi et al.,
1979). This commentary serves as a brief introduction
to a group of accompanying reviews summarizing the
current state of knowledge in some of the most active
areas of IFN research within the context of innate immu-
nity and autoimmunity. My comments will focus on how
views of the field of IFN research (especially of type I IFN)
have been evolving over the nearly 50 year period since
the first publications describing IFN (Table 1).
From Selective Antiviral Inhibitor to Multifunctional
Cytokine
Isaacs, Lindenmann, and other pioneers of IFN research
had not anticipated that the significance of IFN would
extend beyond the field of virology. In fact, an article in
a leading textbook on IFN published more than 15 years
after the original description of IFN proposed that the
‘‘probable lack of other (than antiviral) cellular effects
*Correspondence: jan.vilcek@med.nyu.eduof interferons’’ be part of a definition of IFNs (Lockart,
1973). Yet, as early as 1962, some investigators argued
that murine IFN inhibited the growth of mouse cells in
culture and that this activity could not be separated
from the antiviral action of IFN (Paucker et al., 1962). Al-
most concurrently, IFN was shown to inhibit the appear-
ance of intracellular inclusions formed by Chlamydia
psittaci, an obligate intracellular bacterium (Sueltenfuss
and Pollard, 1962). The latter finding was followed by
demonstrations that type I IFN inhibits intracellular mul-
tiplication of protozoa, rickettsia, and other intracellular
bacteria (reviewed in Stewart, 1979; Vilcek and Jahiel,
1970). Among other early recognized pleiotropic activi-
ties of type I IFNs were also enhancement of the lytic
action of cytotoxic T cells for tumor target cells (Lindahl
et al., 1972) and enhancement of MHC antigen expres-
sion (Lindahl et al., 1976). Other studies revealed that
treatment with IFN can inhibit tumor growth in animals,
an activity now known to be attributable to multiple
mechanisms (Gresser et al., 1969).
Naturally, today no one doubts that type I IFNs have
multiple functions in addition to their well-known ability
to inhibit virus replication. This is also true of IFN-g,
which functions primarily as an immunomodulatory cy-
tokine. It is useful, however, to remind ourselves that
IFN was discovered by virologists who found what
they had been looking for: an antiviral product of virus-
infected cells responsible for viral interference. It took
many years to change the ingrained concept of IFN as
a specific and selective antiviral protein devoid of any
other ‘‘side effects.’’
The real breakthrough in the understanding of the mo-
lecular mechanisms of IFN actions had to await the def-
inition of IFN receptors and elucidation of signal trans-
duction pathways triggered by the ligand-receptor
interactions. During the first decade of IFN research,
the prevailing view was that the IFN molecule itself—
upon entering the cell and perhaps undergoing some
metabolic changes—was the actual inhibitor of virus
replication. Indirect evidence for IFN binding to the cell
surface was first reported in the late 1960s (Friedman,
1967). By the early 1980s, binding studies with radiola-
beled IFN proteins had led to the conclusion that there
are specific high-affinity cell-surface receptors for
IFNs, that different subspecies of type I IFN (IFN-a and
IFN-b) share a common receptor, and that receptors
for type I and type II IFN are distinct (Aguet et al.,
1982; Branca and Baglioni, 1981). Molecular cloning
and characterization of components of type I IFN recep-
tors were largely completed by the mid-1990s (Doman-
ski and Colamonici, 1996; Novick et al., 1994). It is now
clear that all type I IFNs bind to the same dimeric recep-
tor, but different type I IFNs elicit somewhat different
biological responses (van Boxel-Dezaire et al., 2006).
Another important chapter in the annals of IFN re-
search concerns the identification of signaling pathways
responsible for IFN actions. Gradual elucidation of the
details of the JAK-STAT signaling pathway activated
by IFNs helped to clarify not only the molecular mecha-
nisms responsible for IFN actions, but also laid the
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344Table 1. Selected Milestones in Interferon Research
Year Accomplishment or Demonstrationa Referencesb
1957 Description of IFN as virus-inhibitory protein from chick embryo cells
exposed to inactivated flu virus
Isaacs and Lindenmann, 1957
1962 IFN inhibits growth of cultured cells Paucker et al., 1962
IFN inhibits growth of intracellular bacteria Sueltenfuss and Pollard, 1962
1964 IFN induced in animals by bacteria and endotoxin Ho, 1964; Stinebring and Youngner, 1964
1965 Description of IFN-g (type II IFN) Wheelock, 1965
1967 Double-stranded RNA induces IFN Field et al., 1967
1969 IFN inhibits tumor growth in animals Gresser et al., 1969
1972–1976 Immunoregulatory actions of IFN are recognized Lindahl et al., 1976, 1972
1974–1976 IFN-induced proteins mediating antiviral action are described Kerr et al., 1974; Lebleu et al., 1976
1975 Identification of distinct subtypes of type I IFN proteins (IFN-a and -b) Havell et al., 1975
Description of elevated levels of IFN in patients with systemic lupus Skurkovich and Eremkina, 1975
1975–1977 Recognition of IFN’s adverse effects in animals Gresser et al., 1975; Riviere et al., 1977
1979 Isolation and sequencing of human IFN-b cDNA Taniguchi et al., 1979
1980 Isolation, sequencing, and expression of human IFN-a cDNA Nagata et al., 1980
Purification and partial sequencing of human IFN-a and IFN-b proteins Knight et al., 1980; Zoon et al., 1980
1982 Isolation and sequencing of human IFN-g cDNA Gray and Goeddel, 1982
Elevated IFN concentrations described in HIV-infected patients,
correlating with severity of disease
DeStefano et al., 1982
1985 ISRE recognition element identified in upstream region of IFN-inducible genes Friedman and Stark, 1985
1988 Discovery of IRF transcription factor family Miyamoto et al., 1988
1990 Identification of ISGF-3 protein complex mediating activation
of IFN-inducible genes
Fu et al., 1990
1990–1996 Identification and characterization of type I IFN receptor components Novick et al., 1994; Domanski and
Colamonici, 1996
1992–1994 JAK-STAT signaling pathway identified as major pathway for
IFN-induced gene expression
Velazquez et al., 1992; Darnell et al., 1994
1995–1998 IRF-3 and IRF-7 found to play key roles in type I IFN induction Juang et al., 1998; Marie et al., 1998;
Sato et al., 1998
1999 Plasmacytoid dendritic cells are robust producers of type I IFN Siegal et al., 1999
2001 Toll-like receptor 3 shown to recognize double-stranded RNA Alexopoulou et al., 2001
2004–2005 Cytosolic helicases RIG-I and MDA5 can trigger IFN production in
response to double-stranded RNA or RNA viruses
Yoneyama et al., 2004
a Unless otherwise indicated, milestones refer only to research accomplishments in the field of type I IFN research.
b Not all references pertaining to the listed accomplishments or demonstrations could be included.groundwork for understanding the actions of many
other cytokines (Darnell et al., 1994). The nuances and
complexities of the multifaceted biology of type I IFN ac-
tions are reviewed in an accompanying review article
(van Boxel-Dezaire et al., 2006).
Multiple Agents and Multiple Pathways Can Lead
to IFN Induction
Although the recognition that IFN is a pleiotropic cyto-
kine was slow, it had taken less time to learn that
many different stimuli, in addition to viruses, can trigger
IFN production. Thus, IFN production was demon-
strated in chickens, mice, and rabbits injected with a va-
riety of bacteria or bacterial lipopolysaccharide (LPS)
(Ho, 1964; Stinebring and Youngner, 1964). IFN-g owes
its discovery to the finding that the addition of phytohe-
magglutinin, a mitogenic lectin, to a suspension of hu-
man leucocytes elicited IFN production (Wheelock,
1965). Crude filtrates from cultures of the fungus Penicil-
lium stoloniferum were shown to induce IFN in mice and
in tissue culture (Kleinschmidt et al., 1964). (The filtrate
was called ‘‘statolon’’ and shown earlier to have antiviral
activity.) Of special significance was the demonstration
that the active principle of ‘‘statolon,’’ and a similar fun-
gal extract called ‘‘helenine,’’ was double-stranded
RNA—likely originating from a polyhedral virus infecting
the fungal cells. Double-stranded RNA from statolon or
helenine, and also synthetic double-stranded RNA,
poly (I).poly(C), readily triggered IFN production in intactanimals or in cell cultures (Field et al., 1967). Although
hopes of using double-stranded RNA as a therapeutic
agent for virus infections have not materialized, identifi-
cation of double-stranded RNA as a potent IFN inducer
provided researchers with a precious tool for the study
of IFN induction pathways. In addition, it soon became
apparent that double-stranded RNA plays a key role
not only in IFN induction, but also in IFN action. Two of
the IFN-induced proteins central to IFN’s antiviral ac-
tions, 20-50 oligoadenylate synthetase and double-
stranded RNA-dependent protein kinase (PKR), were
shown to require double-stranded RNA for their activa-
tion (Kerr et al., 1974; Lebleu et al., 1976).
It was expected that identification of double-stranded
RNA as a potent IFN inducer in the late 1960s would rap-
idly provide clues to the mechanism of IFN induction by
viruses. After all, double-stranded RNA was known to be
a byproduct of replication of many viruses, so wouldn’t
exposure of cells to double-stranded RNA simply mimic
the process of IFN induction by viruses? In reality, the
situation proved to be more complicated. Molecular
pathways mediating cellular responses to double-
stranded RNA remained largely unknown until the dem-
onstration that toll-like receptor 3 (TLR3) recognizes
double-stranded RNA (Alexopoulou et al., 2001). As ex-
plained in more detail in the accompanying review (Stet-
son and Medzhitov, 2006), this cytosolic pathway is
functional mainly in specialized cells, namely dendritic
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345cells (DCs). It is now apparent that the main pathway of
type I IFN induction by double-stranded RNA and vari-
ous RNA-containing viruses, which can be activated in
a variety of cell types, is triggered by the cytosolic cas-
pase-recruitment domain (CARD)-containing helicases
RIG-I or MDA5 (Kato et al., 2006; Yoneyama et al.,
2004). In addition to double-stranded RNA, other micro-
bial components or products have been shown to trig-
ger type I IFN production through other pathways, in-
cluding single-stranded viral RNA (acting on TLR7 and
TLR8) and viral or bacterial DNA (via TLR9). Although nu-
cleic acids are arguably the most important activators of
type I IFN production, bacterial LPS is now known to
trigger IFN production in macrophages and DCs via
TLR4 (Kawai and Akira, 2006; Stetson and Medzhitov,
2006). Molecular pathways used by other stimuli known
to trigger type I IFN production, e.g., some viral glyco-
proteins and other microbial components, have not yet
been fully elucidated (Malmgaard, 2004).
Another shot in the arm for the study of molecular
mechanisms of IFN induction was provided by the dis-
covery of the new family of transcription factors, the IFN
regulatory factors (IRFs), by Taniguchi and colleagues
(Miyamoto et al., 1988). The earliest-discovered mem-
bers of this family, IRF-1 and IRF-2, were shown to be
important in a variety of innate and adaptive immune re-
sponses, including T helper 1 responses and natural
killer (NK) cell differentiation (Taniguchi et al., 2001).
Two other members of the IRF family, IRF-3 and IRF-7,
have been found to play key roles in type I IFN gene
activation (Juang et al., 1998; Marie et al., 1998; Sato
et al., 1998).
It has also become apparent that several IRF family
members, including IRF-3, -5, and -7, are important in
TLR signaling (Honda and Taniguchi, 2006; Kawai and
Akira, 2006). IRF family transcription factors play
broader roles in TLR signaling that are not limited to
IFN gene activation. For example, MyD88-dependent
activation of IRF-5 is essential for the TLR-mediated in-
duction of the proinflammatory cytokines TNF-a, IL-6,
and IL-12, but not for IFN-a and IFN-b induction
(Takaoka et al., 2005). The molecular pathways of the
complex processes of type I IFN induction are reviewed
in the accompanying articles (Honda et al., 2006; Stet-
son and Medzhitov, 2006).
Good Interferon versus Bad Interferon
In the early days, IFN was believed to be a highly selec-
tive and specific antiviral agent devoid of any actions in
uninfected cells and assumed to be completely nontoxic
in the intact organism. The presumed lack of IFN toxicity
served as an important argument in the effort to develop
IFNs as therapeutic agents for the treatment of viral in-
fections and cancer in the 1970s and early 1980s. And
yet, results suggesting adverse actions of IFNs in the
body were already at hand in the mid-1970s. Thus, injec-
tion of large doses of type I mouse IFN to newborn mice
caused growth retardation and, eventually, death
(Gresser et al., 1975). The major histopathological find-
ing was steatosis and necrosis of the liver. Mice given
sublethal doses of IFN developed glomerulonephritis
later in life. The biological relevance of these findings
was recently corroborated by a study demonstrating
that embryonic lethality seen in DNase II-deficient
mice is due to the animals’ inability to degrade DNAderived from erythroid precursors, which in turn triggers
IFN-b production that induces expression of a specific
set of IFN-responsive genes leading to embryonic le-
thality (Yoshida et al., 2005).
Another surprising development was the gradual real-
ization that endogenous IFN, produced in the body in
the course of an infection, can be harmful—first clearly
demonstrated in the model of lymphocytic choriomenin-
gitis virus (LCMV) infection in newborn mice (Riviere
et al., 1977). Most of LCMV-infected animals died within
2–3 weeks, and surviving mice developed glomerulone-
phritis later in life. However, LCMV-infected newborn
mice treated with a potent neutralizing antibody to
type I mouse IFN survived and had a lower incidence
of glomerulonephritis later in life.
Gradually, other evidence became available suggest-
ing that IFN produced in the course of common virus in-
fections, while serving as an inhibitor of virus replication,
may also contribute to morbidity. Some of this evidence
was gleaned from early clinical studies with natural or re-
combinant IFNs revealing that administration of IFN-a or
IFN-b to patients produced fever, fatigue, malaise, myal-
gia, and anemia (Vilcek, 1984). It became apparent that
similar ‘‘flu-like’’ symptoms seen in many common acute
virus infections are due, at least in part, to the produc-
tion of endogenous IFN. Thus, administration of IFN-
a by intranasal spray protected volunteers from rhinovi-
rus infection. However, intranasal IFN administration
also produced a local inflammatory reaction, not unlike
that seen in patients suffering from naturally acquired
rhinovirus infection (Merigan et al., 1973; Vilcek, 1984).
Another indication of possible adverse effects of IFN
came from studies showing that sera of many patients
with autoimmune diseases, especially patients with sys-
temic lupus erythematosus (SLE), have elevated
amounts of type I IFN (Hooks et al., 1982; Preble et al.,
1982; Skurkovich and Eremkina, 1975). Although the ex-
act significance of these observations was not under-
stood at the time, the fact that the presence of IFN
seemed to correlate with disease activity suggested
a pathogenetic, rather than protective, activity. Further
support for the role of type I IFN in autoimmunity was
gained when it had became apparent that IFN therapy
may sometimes cause or aggravate autoimmune disor-
ders, including thyroiditis, diabetes, arthritis, and vascu-
litis (Banchereau and Pascual, 2006).
Much more information about the source and role of
IFN in SLE and some other autoimmune disorders is
available today, as reviewed in the accompanying article
(Banchereau and Pascual, 2006). A central hypothesis
proposed by these authors is that overproduction of
type I IFN in SLE causes activation of immature myeloid
DCs, which in turn leads to the activation and expansion
of autoreactive T cells and B cells. Further amplification
of autoimmune responses then occurs through addi-
tional interactions involving, among others, TLR7- or
TLR9-mediated activation of plasmacytoid DCs by nu-
cleic acid containing immune complexes.
An interesting concept concerns the crossregulation
of IFN and tumor necrosis factor (TNF) in autoimmunity
(Banchereau and Pascual, 2006; Palucka et al., 2005).
It has been known for a while that some patients treated
with anti-TNF agents may develop anti-nuclear anti-
bodies, antibodies to double-stranded DNA, and in
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346rare occasions, SLE (Feldmann and Maini, 2001). The
latter findings in patients treated with anti-TNF agents
correlate with enhanced IFN production by plasmacy-
toid DCs, suggesting that TNF inhibits type I IFN gener-
ation. Conversely, IFN-b was found to inhibit TNF pro-
duction by microglia, which might partially explain the
beneficial effect of IFN-b in multiple sclerosis (Teige
et al., 2003).
Elevated amounts of type I IFN with properties similar
to the IFN found in the sera of SLE patients were also
demonstrated in a high percentage of AIDS patients
(DeStefano et al., 1982). The presence and the amounts
of IFN in the AIDS patients’ sera generally correlated
with the severity of disease, suggesting that IFN may
contribute to immune dysfunction. However, the possi-
ble mechanisms whereby IFN may contribute to AIDS
pathogenesis remained mysterious for a long time. We
now appreciate the fact that type I IFNs can sensitize
cells to apoptotic signals, especially to virus-induced
apoptosis (see review by Stetson and Medzhitov, 2006
in this issue of Immunity). As far as I know, there exists
no direct evidence that IFN sensitizes CD4+ T cells to
HIV-induced cell death, but such action is a plausible
possibility. It is also possible that depletion of CD4+ T
cells may be an indirect consequence of IFN action. A re-
cently proposed hypothesis links the depletion of CD4+
T cells in HIV-infected patients to IFN’s ability to en-
hance the generation of TNF-related apoptosis-inducing
ligand (TRAIL) and its receptor DR5 (Herbeuval et al.,
2005).
Studies in animals indicate that in certain situations
IFN may promote, rather than inhibit, the multiplication
of an infectious agent. Type I IFN receptor-deficient
mice were shown to be markedly more resistant to infec-
tion with a high dose Listeria monocytogenes (Auerbuch
et al., 2004). At 3 days after inoculation, wild-type mice
contained a thousand times more bacteria in their
spleens than IFN receptor-deficient mice. Resistance
to Listeria infection correlated with elevated amounts
of interleukin 12 in the blood and increased numbers
of spleen macrophages producing TNF. A similar en-
hanced resistance to Listeria was seen in IRF-3-defi-
cient mice (O’Connell et al., 2004). The results of these
studies suggest that Listeria monocytogenes is exploit-
ing an IFN-driven innate immune mechanism to promote
its pathogenesis.
Conclusion
Our understanding of the nature and roles of type I IFNs
is very different today from what it was during the ‘‘ro-
mantic period’’ when nearly supernatural properties
had been attributed to IFN. We now appreciate the
fact that IFNs play important roles in host defenses,
but we understand that they can also be harmful when
produced at the wrong time or wrong place. On the pos-
itive side, although the clinical utility of IFNs has not met
the rosy expectations of some of its most enthusiastic
promoters, several recombinant type I IFN products
have earned a solid foothold in the pharmaceutical
armamentarium. One viral infection in which IFN-a is
widely used (frequently in combination with the nucleo-
side analog Ribavirin) is chronic hepatitis C. Other cur-
rently approved clinical applications of IFN-a are for
the treatment of some neoplasias, including certain
forms of chronic myelogenous leukemia and malignantmelanoma. Recombinant IFN-b is being used for the
treatment of relapsing forms of multiple sclerosis. As is
frequently the case with other therapeutics, a thorough
understanding of the mechanism of IFN’s beneficial ac-
tions in malignancies and in multiple sclerosis has
lagged behind its therapeutic utility.
We have made enormous strides in the understanding
of the molecular mechanisms of regulation of IFN induc-
tion and synthesis and in the elucidation of the mecha-
nisms of IFN action. The most recent advances in these
areas are highlighted in the four accompanying reviews
published in this issue (Banchereau and Pascual, 2006;
Honda et al., 2006; Stetson and Medzhitov, 2006; van
Boxel-Dezaire et al., 2006).
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